Simon Tanguay
Overview
Explore the profile of Simon Tanguay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
2043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ouchene L, Udupa M, Mija L, Moussa S, Chergui M, Watters K, et al.
J Am Acad Dermatol
. 2025 Feb;
PMID: 39984057
No abstract available.
2.
Shrem N, Beltran-Bless A, Ghosh S, Tajzler C, Wood L, Kollmannsberger C, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941888
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium...
3.
Jones J, Jones J, Matthew A, Tanguay S, Higano C, Goldenberg L, et al.
J Urol
. 2025 Jan;
213(4):416.
PMID: 39836882
No abstract available.
4.
Jones J, Matthew A, Tanguay S, Higano C, Goldenberg L, Howell D, et al.
J Urol
. 2024 Dec;
213(4):407-416.
PMID: 39705576
Purpose: Although the provision of a survivorship care plan (SCP) has been recommended after prostate cancer (PCa) treatment, there have been no randomized controlled trials to examine their impact. The...
5.
Soytas M, Dragomir A, Sawaya G, Hesswani C, Tanguay M, Finelli A, et al.
BJU Int
. 2024 Dec;
PMID: 39631366
Objective: To evaluate and compare the outcomes of patients with localised renal cell carcinoma (RCC) with and without sarcomatoid features and the impact of this on cancer recurrence and survival....
6.
Robert A, Mallick R, McIsaac D, Lavallee L, Bhindi B, Heng D, et al.
J Urol
. 2024 Dec;
213(4):455-466.
PMID: 39622017
Purpose: Postoperative prognostic tools allow for improved prediction of future recurrence risk, patient counseling, assessment of eligibility for adjuvant treatments, and appropriate follow-up surveillance. The purpose of this analysis was...
7.
Hesswani C, Avolio P, Rompre-Brodeur A, Ghai S, Anidjar M, Kinnaird A, et al.
J Endourol
. 2024 Nov;
PMID: 39612186
This article equips Canadian urologists with the latest advancements in focal therapy (FT) principles and outcomes while providing an overview of its current landscape in Canada, including challenges and future...
8.
Graham J, Ahmad A, Basappa N, Bernhard J, Bhindi B, Bosse D, et al.
Can Urol Assoc J
. 2024 Nov;
18(11):E371-E386.
PMID: 39500366
No abstract available.
9.
Park C, Moria F, Ghosh S, Wood L, Bjarnason G, Bhindi B, et al.
Curr Oncol
. 2024 Aug;
31(8):4704-4712.
PMID: 39195334
Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit for select patients with...
10.
Glennon K, Endo M, Usui Y, Iwasaki Y, Breau R, Kapoor A, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2400094.
PMID: 39088769
Purpose: Genetic susceptibility to nonsyndromic renal cell carcinoma (RCC) remains poorly understood, especially for different histological subtypes, as does variations in genetic predisposition in different populations. The objectives of this...